CliffBio
small molecule

HYDROFLUMETHIAZIDE

HYDROFLUMETHIAZIDE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameHYDROFLUMETHIAZIDE
Active ingredientHYDROFLUMETHIAZIDE
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 1985
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

HYDROFLUMETHIAZIDE patent cliff — loss of exclusivity — | CliffBio